This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

IHD (SAVE trial)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

2231 patients with asymptomatic left ventricular dysfunction (ejection fraction <= 40%) were randomised to:

  • oral captopril
  • placebo

Randomisation to drug or placebo took place 3-16 days post-MI (mean 11 days).

The SAVE trial demonstrated that:

  • captopril reduced mortality from all causes (20% vs. 25%)
  • captopril reduced mortality attributed to cardiovascular events (21% reduction in risk)

The investigators concluded that long-term therapy with captopril is indicated in patients who have left ventricular dysfunction post-myocardial infarction.

Reference:

  • (1) Pfeffer, MA. et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 327(10), 669-77.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.